Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update notes Polatuzumab Vedotin in combination chemotherapy for previously untreated diffuse large B-cell lymphoma and related high-gr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Double Expressor Lymphoma
• High-grade B-cell Lymphoma
• High-grade B-cell Lymphoma with Myc Bcl2 Bcl6 Rearrangements
• High-grade B-cell Lymphoma with Myc and Bcl2 or Bcl6 Rearrangements

Drugs mentioned

• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements | Phase 2 | Status: ACTIVE_NOT_RECRUITING